Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults wit…
Biotechnology
US, Philadelphia [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Amicus Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2016 | -1.2000 | -1.400 | 0 | 5 | -132 | -413 | -123 | -3 | -126 | -3 | 47 | 3 |
| 2017 | -1.4900 | -1.599 | 4 | 35 | -200 | -235 | -175 | -350 | -175 | -362 | 71 | 25 |
| 2018 | -1.8500 | -1.741 | 36 | 89 | -284 | -328 | -197 | -305 | -210 | -312 | 88 | 62 |
| 2019 | -1.8800 | -1.380 | 91 | 179 | -348 | -407 | -316 | -117 | -325 | -120 | 127 | 125 |
| 2020 | -1.4800 | -1.021 | 182 | 261 | -356 | -301 | -328 | -171 | -300 | -175 | 169 | 182 |
| 2021 | -1.0700 | -0.782 | 260 | 307 | -276 | -213 | -232 | -171 | -243 | -174 | 156 | 167 |
| 2022 | -0.9200 | -0.775 | 305 | 327 | -250 | -244 | -196 | -204 | -199 | -219 | 192 | 191 |
| 2023 | -0.8200 | -0.450 | 329 | 398 | -236 | -119 | -191 | -232 | -204 | -249 | 213 | 217 |
| 2024 | -0.5100 | -0.185 | 399 | 517 | -151 | -54 | -65 | -339 | -73 | -348 | 275 | 361 |
| 2025 | - | 0.178 | - | 640 | - | 54 | - | -420 | - | -431 | - | 448 |
| 2026 | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F10X/td> | - | 2.F101/td> | - | 2.F101 | - | 2.F101 |
| 2027 | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F11X/td> | - | 1.F111/td> | - | 1.F111 | - | 1.F111 |
| 2028 | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F12X/td> | - | 0.F121/td> | - | 0.F121 | - | 0.F121 |